8-K
AIM ImmunoTech Inc. (AIM)
View as plain text
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Dateof Report September 22, 2023
AIM
IMMUNOTECH INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-27072 | 52-0845822 |
|---|---|---|
| (state<br> or other jurisdiction | (Commission | (I.R.S.<br> Employer |
| of<br> incorporation) | File<br> Number) | Identification<br> No.) |
| 2117 SW Highway 484, Ocala FL | 34473 | |
| --- | --- | |
| (Address<br> of principal executive offices) | (Zip<br> Code) |
Registrant’s
telephone number, including area code: (352) 448-7797
AIM Immunotech Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> Symbol | Name<br> of each exchange on which registered |
|---|---|---|
| Common<br> Stock, par value $0.001 per share | AIM | NYSE<br> American |
Item7.01. Regulation FD Disclosure.
Furnished herewith as Exhibits 99.1 is a presentation entitled Rintatolimod (Ampligen®): Overview of Ampligen’s Clinical Progressin Oncology that Christopher McAleer, Ph.D., our Scientific Officer, will present at the Marie Sklodowska-Curie Symposium on Cancer Research and Care at Roswell Park Cancer Center on September 22, 2023. This presentation is posted in the subsection of the “Investors” tab on our website at https://AIMImmuno.com.
Also furnished is a press release dated September 22, 2023 about the presentation.
This information, including Exhibits 99.1 and 99.2, referenced herein, are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. They may only be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference in such filing.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits.
EXHIBIT
INDEX
| Exhibit No. | Description |
|---|---|
| 99.1 | Presentation entitled Rintatolimod (Ampligen®): Overview of Ampligen’s Clinical Progress in Oncology Long COVID Q3 2023. |
| 99.2 | Press Release about the Presentation dated September 22, 2023. |
| 104 | Cover<br> Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AIM<br> IMMUNOTECH INC. | ||
|---|---|---|
| September<br> 22, 2023 | By: | /s/ Thomas K. Equels |
Exhibit 99.1
Exhibit 99.2
AIMImmunoTech Selected to Present at the 3^rd^Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
OCALA,FL (September 22, 2023) – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3^rd^ Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023. In addition to the presentation, the Company is proud to announce its sponsorship of the event.
Details for the presentation are as follows:
**Title:**Rintatolimod (Ampligen®): Overview of Ampligen’s Clinical Progress in Oncology
**Presenter:**Christopher McAleer, Ph.D.
**Session:**Session 7: Team Science: National and International Collaborations with NGOs, Academia, Pharma, & Biotech
**Date:**Friday, September 22, 2023
For more information about the conference, visit: https://www.roswellpark.org/msc-symposium.
The presentation will be available on the AIM website once presented at the conference.
AboutAIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.
InvestorContact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com